[en] CONTEXT: Acromegaly is a rare disease associated with chronic multisystem complications. National registries have been created in several countries. DESIGN: The French registry contains data on acromegaly epidemiology, management and comorbidities recorded over more than three decades, retrospectively until 1999 and prospectively from 1999 until 2012. RESULTS: Data could be analyzed for 999 of the 1034 patients included in the registry (46% males). Disease control, defined as IGF-I normalization (adjusted for age and sex), was achieved in 75% of patients at the last follow-up visit. Half the patients with uncontrolled disease had IGF-I levels below 1.5 times the upper limit of normal (ULN). The proportion of patients with surgically cured disease did not change markedly over time, whereas the proportion of patients with uncontrolled disease fell and the proportion of patients with medically controlled disease rose. Cardiovascular, metabolic, respiratory and rheumatologic comorbidities and their outcomes were recorded for most patients, and no noteworthy overall deterioration was noted over time. Cancer occurred in 10% of patients, for a standardized incidence ratio of 1.34 (95% CI, 0.94-1.87) in men and 1.24 (0.77-1.73) in women. Forty-one patients died during follow-up, for a standardized mortality ratio of 1.05 (0.70-1.42). Most deaths were due to cancer. CONCLUSIONS: The majority of patients with acromegaly now have successful disease control thanks to multistep management. The incidence of comorbidities following diagnosis of acromegaly is very low. Life expectancy is now close to that of the general population, probably owing to better management of the GH/IGF-I excess and comorbidities.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Maione, Luigi
Brue, Thierry
Beckers, Albert ; Université de Liège > Département des sciences cliniques > Endocrinologie
Delemer, Brigitte
PETROSSIANS, Patrick ; Centre Hospitalier Universitaire de Liège - CHU > Service d'endocrinologie clinique
Borson-Chazot, Francoise
Chabre, Olivier
Francois, Patrick
Bertherat, Jerome
Cortet, Christine
Chanson, Philippe
Language :
English
Title :
Changes in the management and comorbidities of acromegaly over three decades. The French Acromegaly Registry.
Chanson P, Salenave S & Kamenicky P. Acromegaly. Handbook of Clinical Neurology 2014 124 197-219. (doi:10.1016/B978-0-444-59602-4.00014-9)
Colao A, Ferone D, Marzullo P & Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 2004 25 102-152. (doi:10.1210/er.2002-0022)
Melmed S. Medical progress: acromegaly. New England Journal of Medicine 2006 355 2558-2573. (doi:10.1056/NEJMra062453)
Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K & Melmed S. A consensus on criteria for cure of acromegaly. Journal of Clinical Endocrinology and Metabolism 2010 95 3141-3148. (doi:10.1210/jc.2009-2670)
Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW & Ho KK. Expert consensus document: A consensus on the medical treatment of acromegaly. Nature Reviews Endocrinology 2014 10 243-248. (doi:10.1038/nrendo.2014.21)
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A & Wass JA. Acromegaly: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2014 99 3933-3951. (doi:10.1210/jc.2014-2700)
Holdaway IM, Rajasoorya RC & Gamble GD. Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 667-674. (doi:10.1210/jc.2003-031199)
Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P & Laine H. A nationwide survey of mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 4081-4086. (doi:10.1210/jc.2004-1381)
Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K & Maiter D. AcroBel the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. European Journal of Endocrinology 2007 157 399-409. (doi:10.1530/EJE-07-0358)
Anagnostis P, Efstathiadou ZA, Polyzos SA, Adamidou F, Slavakis A, Sapranidis M, Litsas ID, Katergari S, Selalmatzidou D & Kita M. Acromegaly: presentation, morbidity and treatment outcomes at a single centre. International Journal of Clinical Practice 2011 65 896-902. (doi:10.1111/j.1742-1241.2011.02682.x)
Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, Pivonello R, Grottoli S, Losa M & Cannavo S. Predictors of morbidity and mortality in acromegaly: an Italian survey. European Journal of Endocrinology 2012 167 189-198. (doi:10.1530/EJE-12-0084)
Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T & Moreno B. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). European Journal of Endocrinology 2004 151 439-446. (doi:10.1530/eje.0.1510439)
Sesmilo G, Gaztambide S, Venegas E, Pico A, Del Pozo C, Blanco C, Torres E, Alvarez-Escola C, Fajardo C & Garcia R. Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary 2013 16 115-121. (doi:10.1007/s11102-012-0384-x)
Vallette S, Ezzat S, Chik C, Ur E, Imran SA, Van Uum S, Rivera J, Caspar-Bell G & Serri O. Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clinical Endocrinology 2013 79 79-85. (doi:10.1111/cen. 12112)
Salvatori R, Woodmansee WW, Molitch M, Gordon MB & Lomax KG. Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary 2014 17 13-21. (doi:10.1007/s11102-012-0460-2)
Howlett TA, Willis D, Walker G, Wass JA, Trainer PJ & Group UKARS. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clinical Endocrinology 2013 79 689-699. (doi:10.1111/cen. 12207)
Kwon O, Song YD, Kim SY, Lee EJ & Rare Disease Study Group, Science and Research Committee, Korean Endocrine Society. Nationwide survey of acromegaly in South Korea. Clinical Endocrinology 2013 78 577-585. (doi:10.1111/cen. 12020)
Schofl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, Mayr B, Schopohl J & Participants of the German Acromegaly Register. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. European Journal of Endocrinology 2013 168 39-47. (doi:10.1530/EJE-12-0602)
Vandeva S, Elenkova A, Natchev E, Kirilov G, Tcharaktchiev D, Yaneva M, Kalinov K, Marinov M, Hristozov K & Kamenov Z. Treatment outcome results from the Bulgarian Acromegaly Database: adjuvant dopamine agonist therapy is efficient in less than one fifth of non-irradiated patients. Experimental and Clinical Endocrinology and Diabetes 2015 123 66-71. (doi:10.1055/s-0034-1389987)
Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LO, Laurberg P, Pedersen L, Dekkers OM, Sorensen HT & Jorgensen JO. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. European Journal of Endocrinology 2016 175 181-190. (doi:10.1530/EJE-16-0117)
Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe-Diaz AM, Garcia-Dominguez A, Reza-Albarran AA, Cuevas-Ramos D, Melgar V, Talavera J & Rivera-Hernandez AJ. The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. Journal of Clinical Endocrinology and Metabolism 2016 101 3997-4004. (doi:10.1210/jc.2016-1937)
Mercieca C, Gruppetta M & Vassallo J. Epidemiology, treatment trends and outcomes of acromegaly. European Journal of Internal Medicine 2012 23 e206-e207. (doi:10.1016/j.ejim.2012.07.010)
Dupuy O, Petrossian T, Bordier L, Mayaudon H & Bauduceau B. Hypertension and acromegaly in the elderly: French Registry Data. Archives des Maladies du Coeur et des Vaisseaux 2007 100 660-663.
Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, Borson-Chazot F, Brue T, Delemer B & French Acromegaly Registry. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. European Journal of Endocrinology 2011 164 877-884. (doi:10.1530/eje-10-1050)
Colao A, Amato G, Pedroncelli AM, Baldelli R, Grottoli S, Gasco V, Petretta M, Carella C, Pagani G & Tambura G. Gender- and agerelated differences in the endocrine parameters of acromegaly. Journal of Endocrinological Investigation 2002 25 532-538. (doi:10.1007/BF03345496)
Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529. (doi:10.1210/jc.85.2.526)
Giustina A & Melmed S. Acromegaly consensus: the next steps. Journal of Clinical Endocrinology and Metabolism 2003 88 1913-1914. (doi:10.1210/jc.2002-021649)
Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P & Kleinberg D. Consensus statement: medical management of acromegaly. European Journal of Endocrinology 2005 153 737-740. (doi:10.1530/eje.1.02036)
Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA & Giustina A. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013 16 294-302. (doi:10.1007/s11102-012-0420-x)
Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clinical Chemistry 2011 57 555-559. (doi:10.1373/clinchem.2010.150631)
Chanson P, Arnoux A, Mavromati M, Brailly-Tabard S, Massart C, Young J, Piketty ML, Souberbielle JC & VARIETE Investigators. Reference values for IGF-I serum concentrations: comparison of six immunoassays. Journal of Clinical Endocrinology and Metabolism 2016 101 3450-3458. (doi:10.1210/jc.2016-1257)
Schofl C, Grussendorf M, Honegger J, Tonjes A, Thyroke-Gronostay D, Mayr B, Schopohl J & Participants of German Acromegaly Register. Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey. European Journal of Endocrinology 2015 172 351-356. (doi:10.1530/eje-14-0844)
Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, Jervis P, Roldan P, Mendoza V & Lopez-Felix B. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. Journal of Clinical Endocrinology and Metabolism 2014 99 4438-4446. (doi:10.1210/jc.2014-2670)
Roelfsema F, Biermasz NR & Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 2012 15 71-83. (doi:10.1007/s11102-011-0347-7)
Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB & Wilson CB. Transsphenoidal microsurgery for growth hormonesecreting pituitary adenomas: initial outcome and long-term results (In Process Citation). Journal of Clinical Endocrinology and Metabolism 1998 83 3411-3418. (doi:10.1210/jcem.83.10.5111)
Chanson P, Brue T, Delemer B, Caron P, Borson-Chazot F, Zouater H & Medecinsde l'Etude A. Pegvisomant treatment in patients with acromegaly in clinical practice: the French ACROSTUDY. Annales d'Endocrinologie 2015 76 664-670. (doi:10.1016/j. ando.2015.10.003)
Kuhn E, Maione L, Bouchachi A, Roziere M, Salenave S, Brailly-Tabard S, Young J, Kamenicky P, Assayag P & Chanson P. Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. European Journal of Endocrinology 2015 173 693-702. (doi:10.1530/EJE-15-0500)
van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N & Strasburger CJ. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. Journal of Clinical Endocrinology and Metabolism 2012 97 1589-1597. (doi:10.1210/jc.2011-2508)
Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K & Dhillo WS. The effects of long-term growth hormone and insulinlike growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clinical Endocrinology 2011 75 220-225. (doi:10.1111/j.1365-2265.2011.04019.x)
Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, Bates AS & Stewart PM. Mortality in patients with pituitary disease. Endocrine Reviews 2010 31 301-342. (doi:10.1210/er.2009-0033)
Olarescu NC, Heck A, Godang K, Ueland T & Bollerslev J. The metabolic risk in patients newly diagnosed with acromegaly is related to fat distribution and circulating adipokines and improves after treatment. Neuroendocrinology 2016 103 197-206. (doi:10.1159/000371818)
Reyes-Vidal C, Fernandez JC, Bruce JN, Crisman C, Conwell IM, Kostadinov J, Geer EB, Post KD & Freda PU. Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk. Journal of Clinical Endocrinology and Metabolism 2014 99 4124-4132. (doi:10.1210/jc.2014-2259)
Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G & Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: a metaanalysis. World Journal of Gastroenterology 2008 14 3484-3489. (doi:10.3748/wjg.14.3484)
Boguszewski CL & Ayuk J. Management of endocrine disease: acromegaly and cancer: an old debate revisited. European Journal of Endocrinology 2016 175 R147-R156. (doi:10.1530/EJE-16-0178)